Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nova Eye Medical ( (AU:EYE) ) has shared an update.
Nova Eye Medical reported quarterly sales of US$5.8 million to 31 March 2026, a 23% increase on the prior corresponding period, driven by strong U.S. demand and initial iTrack Advance sales in China. Last-twelve-month revenue rose 24% to about US$22 million, with U.S. sales up 28% and a compound quarterly growth rate of roughly 6% over the past six quarters.
The company materially reduced its quarterly EBITDA loss to US$75,000 from US$482,000 a year earlier, despite a group operating cash outflow of A$1.2 million influenced by advance payments and currency movements. Management reaffirmed guidance for breakeven or slightly positive EBITDA in the second half of FY26, nudged FY26 sales guidance ex-China to US$21–22 million, and flagged further improvement in operating cash flow, underscoring continued momentum toward profitability.
More about Nova Eye Medical
Nova Eye Medical is an ASX-listed medical technology company focused on advanced ophthalmic treatment technologies and devices for glaucoma. The company’s core product, iTrack Advance, targets minimally invasive glaucoma surgery, with a primary commercial focus on the United States and expanding international markets including China and Europe.
Average Trading Volume: 329,625
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$38.45M
See more data about EYE stock on TipRanks’ Stock Analysis page.